Concord Biotech Limited (CONCORDBIO) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹598.4 (-2.25% day change)
Key ratios
- P/E ratio
- 48.3
- P/B ratio
- 5.32
- ROE (%)
- 12.93
- ROCE (%)
- 14.18
- Debt/Equity
- 0
- Dividend yield (%)
- 1.04
- Market cap (₹ Cr)
- 12,520.47
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 16.95 · Beneish M-Score: -2.14
InvestSights quality score
56.5/100 — Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The central signal is that Concord’s core API franchise has regained broad-based momentum, but the next phase of earnings quality depends on converting underutilised growth investments into revenue. Q2 API revenue grew 30%, supported by immunosuppressants, anti-infectives, antifungals and oncology, while management retained confidence in growth slightly above its historical…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.